Galvokimig

Approval Year

Name

Type

Language

Galvokimig

Official Name

English

Immunoglobulin G1, anti-(human interleukin 17A/interleukin 17F) (human-Rattus norvegicus γ1-chain C-terminal fragment) fusion protein with peptide linker (SGGGGTGGGGS) fusion protein with immunoglobulin [283-cysteine,483-cysteine] anti-(human serum albu

Common Name

English

galvokimig [INN]

Common Name

English

Immunoglobulin G1(VH-CH1-h)-scFv_L-kappa-scFv, anti-[Homo sapiens IL17A (interleukin 17A, IL-17A) and IL17F (interleukin 17F, IL-17F)], anti-[Homo sapiens IL13 (interleukin 13, IL-13)], anti-[Homo sapiens ALB (albumin, human serum albumin, HSA], humanize

Common Name

English

Fused G1(VH-CH1-h)-scFv heavy-kappa heavy chain humanized (1-492) [VH-IGHG1 CH1-h anti-IL-17A/F humanized (1-228) [VH (Homo sapiens IGHV3-7*01 (88.7%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125)-Homo sapiens IG

Common Name

English

Code System Code Type Description

CAS

2648456-30-6

Created by admin on Sat Dec 16 19:58:14 GMT 2023 , Edited by admin on Sat Dec 16 19:58:14 GMT 2023

PRIMARY

FDA UNII

85A4592PC8

Created by admin on Sat Dec 16 19:58:14 GMT 2023 , Edited by admin on Sat Dec 16 19:58:14 GMT 2023

PRIMARY

INN

12378

Created by admin on Sat Dec 16 19:58:14 GMT 2023 , Edited by admin on Sat Dec 16 19:58:14 GMT 2023

PRIMARY

ACTIVE MOIETY


					85A4592PC8

Galvokimig